Lewis Sanders
Sanders Capital
Lewis Sanders Merck & Company Inc stake
total: 128
Sanders Capital MRK trades
- Total transactions:
- 28
- New positions:
- 1
- Sold out:
- 1
- Added:
- 15
- Reduced:
- 11
- Held since:
- 2015 Q2
- Held for:
- 28 quarters
- Latest activity:
- 2022 Q2
According to 2026 Q1 report, Lewis Sanders doesn't hold any Merck & Company Inc (MRK) shares. To date, the estimated cost basis is nearly $57.74 for "buy" trades and estimated average "sell" price is $65.25. Sanders Capital first purchased MRK in 2015 Q2, initially acquiring about 8.96M shares. Since the initial investment in Merck & Company Inc (MRK), Sanders Capital has made 27 more transactions.
When did Lewis Sanders sell Merck & Company Inc (MRK)?
Lewis Sanders sold off the entire Merck & Company Inc (MRK) position in 2022 Q2.
When did Lewis Sanders buy Merck & Company Inc (MRK)?
Lewis Sanders first invested in Merck & Company Inc (MRK) in 2015 Q2 at the reported quarter-end price of $56.93 per share.
What's the cost basis of Sanders Capital's MRK stake?
The estimated cost basis for Merck & Company Inc (MRK) stake is around $57.74 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $57.74
- Weighted AVG sell price:
- $65.25
Lewis Sanders's historical trades in Merck & Company Inc
28 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$81.85
|
|
-100% (-1,344)
|
-0%
|
|
2021 Q4
|
0.00%
|
1,344
|
$76.64
|
$103,000
|
-99.82% (-744,278)
|
-0.13%
|
|
2021 Q3
|
0.13%
|
745,622
|
$75.11
|
$56,004,000
|
+1.12% (+8,280)
|
+0%
|
|
2021 Q2
|
0.13%
|
737,342
|
$77.77
|
$57,343,000
|
-1.34% (-10,040)
|
-0%
|
|
2021 Q1
|
0.14%
|
747,382
|
$77.09
|
$57,616,000
|
-0.31% (-2,300)
|
-0%
|
|
2020 Q4
|
0.16%
|
$81.80
|
+16.23% (+104,700)
|
|||
|
2020 Q3
|
0.18%
|
$82.95
|
-12.64% (-93,311)
|
|||
|
2020 Q2
|
0.21%
|
$77.33
|
+5.08% (+35,709)
|
|||
|
2020 Q1
|
0.25%
|
$76.94
|
-8.52% (-65,400)
|
|||
|
2019 Q4
|
0.25%
|
$90.95
|
+22.53% (+141,200)
|
|||
|
2019 Q3
|
0.24%
|
$84.18
|
-76.70% (-2,062,988)
|
|||
|
2019 Q2
|
1.04%
|
$83.85
|
+2.48% (+65,000)
|
|||
|
2019 Q1
|
1.05%
|
$83.17
|
+2.53% (+64,800)
|
|||
|
2018 Q4
|
1.09%
|
$76.41
|
-21.45% (-698,900)
|
|||
|
2018 Q3
|
1.16%
|
$70.94
|
-8.88% (-317,684)
|
|||
|
2018 Q2
|
1.16%
|
$60.70
|
+4.62% (+157,800)
|
|||
|
2018 Q1
|
1.03%
|
$54.47
|
-4.67% (-167,500)
|
|||
|
2017 Q4
|
1.10%
|
$56.27
|
-63.13% (-6,140,191)
|
|||
|
2017 Q3
|
3.76%
|
$64.03
|
-19.30% (-2,326,148)
|
|||
|
2017 Q2
|
4.96%
|
$64.09
|
+3.96% (+458,950)
|
|||
|
2017 Q1
|
4.99%
|
$64.90
|
+3.25% (+365,276)
|
|||
|
2016 Q4
|
4.70%
|
$58.87
|
+1.56% (+172,426)
|
|||
|
2016 Q3
|
5.45%
|
$62.41
|
+0.68% (+74,900)
|
|||
|
2016 Q2
|
5.25%
|
$57.61
|
+0.21% (+22,797)
|
|||
|
2016 Q1
|
5.01%
|
$52.91
|
+14.23% (+1,365,146)
|
|||
|
2015 Q4
|
4.64%
|
$52.82
|
+3.73% (+345,000)
|
|||
|
2015 Q3
|
4.59%
|
$49.39
|
+3.19% (+286,300)
|
|||
|
2015 Q2
|
4.81%
|
$56.93
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.